Oncomatryx Biopharma S.A.

4 trials 3 recruiting Commercial sponsor Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

0 Completed trials

1 Countries active

5 Unique IMPs

N/A Results reported

Phase I/II

Phase I

Phase I (Other)

Phase I/II: 2 Phase I: 1 Phase I (Other): 1

Top IMPs

OMTX705 2 TISLELIZUMAB 2 CARBOPLATIN 1 PEMETREXED 1 REGORAFENIB 1

All trials

4 total

Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending

2025-521989-95-00 Phase I/II 1 country CARBOPLATIN; OMTX705; PEMETREXED; TISLELIZUMAB
OMTX705-006 Phase 1b Recruiting

2025-521872-69-00 Phase I (Other) 1 country
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting

2025-520743-33-00 Phase I/II 1 country OMTX705; REGORAFENIB; TISLELIZUMAB
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination … Recruiting

2024-514746-36-00 Phase I 1 country

Showing 1–4 of 4 trials

← All sponsors A–Z